Madrigal Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.
Late-breaking AI-based analysis of MAESTRO-NASH biopsy data demonstrates Rezdiffra improved key fibrotic features that are predictive of progression to decompensated cirrhosisNoninvasive test data through three years of treatment demonstrate durable treatment response to Rezdiffra; 91% of patients achieved improvement or stabilization of liver stiffness First analysis of health-related quality of life data from MAESTRO-NASH demonstrates Rezdiffra improved patient worry, health distress and stigm
Madrigal stock plummeted Wednesday on detailed results from a study of Eli Lilly's weight-loss drug in patients with a serious liver disease.